Vimarsana
Biggest News Aggregation in the World

Page 25 - Children Aged News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Children Aged. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Children Aged Today - Breaking & Trending Today

New Dupixent® (dupilumab) Analyses at Two Upcoming Dermatology Congresses Reinforce Long-term Safety and Efficacy Profile in Patients with Atopic Dermatitis as Young as 6 Years - Vimarsana News

New Dupixent® (dupilumab) Analyses at Two Upcoming Dermatology Congresses Reinforce Long-term Safety and Efficacy Profile in Patients with Atopic Dermatitis as Young as 6 Years

Share this article TARRYTOWN, N.Y., April 23, 2021 /PRNewswire/ --  Nearly 30 data presentations at AAD and ESPD highlight the impact of Dupixent on disease measures including rapid itch relief and sustained improvement in disease severity, as well as quality of life in clinical and real-world settings Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that new analyses of Dupixent ® (dupilumab) in patients as young as 6 years with moderate-to-severe atopic dermatitis will be presented at the American Academy of Dermatology Annual Meeting (AAD VMX 2021) from April 23-25, and at ...

Electric Toothbrush Market Size to Reach USD 2163 Million by 2026 at a CAGR 5.7% - Vimarsana News

Electric Toothbrush Market Size to Reach USD 2163 Million by 2026 at a CAGR 5.7%

(1) BANGALORE, India, March 4, 2021 /PRNewswire/ -- The Electric Toothbrush Market is Segmented by Type (Rechargeable, Battery), by Application (Adults, Children), Opportunity Analysis and Industry Forecast, 2021-2027. This report is published on Valuates Reports in the Hygiene & Toiletries Category. The global Electric Toothbrush market was valued at USD 1628 Million in 2019 and is expected to reach USD 2163 Million by the end of 2026, growing at a CAGR of 5.7% during 2021-2026. Major factors driving the growth of electric toothbrush market size are: Rise in awareness towards oral hygiene...

New Dupixent® (dupilumab) Data Showcasing Improvements Across Four Type 2 Inflammatory Diseases to be Presented at 2021 AAAAI Annual Meeting - Vimarsana News

New Dupixent® (dupilumab) Data Showcasing Improvements Across Four Type 2 Inflammatory Diseases to be Presented at 2021 AAAAI Annual Meeting

New Dupixent® (dupilumab) Data Showcasing Improvements Across Four Type 2 Inflammatory Diseases to be Presented at 2021 AAAAI Annual Meeting News provided by Share this article TARRYTOWN, N.Y. and PARIS, Feb. 1, 2021 /PRNewswire/ --  Improvements were noted across key disease measures in certain patients with asthma, atopic dermatitis, eosinophilic esophagitis and chronic rhinosinusitis with nasal polyposis New analyses build on a robust body of evidence reinforcing the role of Dupixent in certain diseases driven by type 2 inflammation Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sano...